The objective is to evaluate the efficacy and safety of the Inspiron™ EVO drug-eluting stent in complex coronary lesions in a real-world population. Patients with symptomatic ischemic heart disease due to lesions in native coronary arteries and restenotic lesions will be treated with the Inspiron™ EVO drug-eluting stent.
Individuals aged 18 years or older presenting with complex coronary lesions requiring percutaneous coronary intervention (PCI).
Individuals who provide consent and are willing to comply with the follow-up protocol.
Individuals who received treatment with the Inspiron™ EVO Stent.
Individuals with lesions ≥ 30 mm in length (Subprotocol 1).
Lesions in saphenous vein grafts or internal mammary grafts.
Contraindication to the use of a drug-eluting stent.
Individuals who were treated during the index procedure with any stent other than the Inspiron™ EVO Stent.